Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical firm focused on developing therapies for unmet medical needs, announced that Dr. Laxminarayan Bhat, the company's Founder and CEO, will participate in a key opinion leader (KOL) webinar hosted by Alliance Global Partners on October 10, 2025. Set for 11:00 AM ET, the event will include a fireside chat featuring Dr. Bhat alongside notable KOLs such as Dr. Larry Ereshefsky and Dr. Mark Opler. The discussion will center around the significant unmet medical needs for patients with schizophrenia, as well as the phase 3 clinical data for Reviva's lead drug candidate, brilaroxazine.

Brilaroxazine (RP5063) represents a pivotal advancement in the treatment of schizophrenia, aiming to address complexities within the disease's treatment landscape. The inclusion of expert KOLs in this forum underscores the importance of peer insights in evaluating the drug's clinical development and future impact on patient care.

Reviva specializes in the discovery and commercialization of next-generation therapeutics, targeting not only CNS disorders but also inflammatory and cardiometabolic diseases. The company is developing a robust pipeline, which includes brilaroxazine and another drug candidate, RP1208. Both candidates have secured composition of matter patents across the United States, Europe, and other regions, signifying Reviva's commitment to innovation in treating critical health issues.

Investors and interested parties can register for the event online, and a replay will be made available on Reviva's investor relations website following the live discussion. This webinar exemplifies Reviva's ongoing efforts to engage with stakeholders and disseminate crucial information regarding its advancements and strategic objectives within the pharmaceutical landscape.

Investors should closely monitor Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) in light of its forthcoming participation in a key opinion leader (KOL) webinar hosted by Alliance Global Partners on October 10, 2025. The webinar will feature a discussion about the critical unmet needs in the treatment landscape for schizophrenia, focusing on Reviva’s lead drug candidate, brilaroxazine, which is currently advancing through phase 3 clinical trials.

Reviva’s therapeutic pipeline, especially brilaroxazine, presents an attractive opportunity for investors due to its innovative nature and the potential to address significant gaps in treatment for central nervous system disorders. The involvement of respected KOLs like Dr. Larry Ereshefsky and Dr. Mark Opler in the webinar underscores the scientific credibility and potential of Reviva’s offerings. Their insights could provide crucial information about the competitive landscape, comparative advantages of brilaroxazine, and the overall clinical and commercial viability of Reviva’s pipeline.

Currently, mental health issues, including schizophrenia, represent a pressing public health challenge, with many existing treatments failing to provide conducive outcomes for patients. Reviva’s focus on innovative therapies in this domain aligns with growing demand for effective mental health solutions, indicating potential market expansion.

Investors should consider the implications of the upcoming data release and expert discussions on the prospects for Regiva’s stock performance. Positive feedback regarding brilaroxazine's clinical data may lead to heightened interest from both institutional and retail investors, potentially boosting RVPH's share price. Conversely, any negative feedback could suppress the stock.

In conclusion, active participation in the KOL webinar could serve as a pivotal moment for Reviva, opening doors for strategic partnerships or increased investment. As a result, investors should remain vigilant around this event and evaluate their positions based on subsequent insights and developments.